These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 6152088)

  • 1. [Comparison of the antilipemic effect of bezafibrate with that of piperazine-sultosilate (A 585). A crossed double-blind study].
    Vinazzer H
    Wien Klin Wochenschr; 1984 Dec; 96(24):889-93. PubMed ID: 6152088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind cross-over study of the effect of sultosilic acid piperazine salt (A-585) and bezafibrate in primary hyperlipoproteinemia.
    Vinazzer H; Farine JC
    Atherosclerosis; 1983 Nov; 49(2):109-18. PubMed ID: 6686778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients.
    Waysbort J; Schwartz S; Brunner D
    Arzneimittelforschung; 1994 Nov; 44(11):1217-22. PubMed ID: 7893284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women.
    Ushiroyama T; Sakuma K; Nosaka S
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):142-8. PubMed ID: 16891292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].
    Lageder H
    Wien Klin Wochenschr; 1980 Feb; 92(3):95-101. PubMed ID: 6985560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
    Bruneder H; Klein HJ
    Dtsch Med Wochenschr; 1981 Dec; 106(49):1653-6. PubMed ID: 7308007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Machalke K; Djaja S; Richter E
    Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613
    [No Abstract]   [Full Text] [Related]  

  • 10. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation.
    Hidalgo L; Zambrana JL; Blanco-Molina A; López-Granados A; Concha M; Casares J; Jiménez-Pérez J; López-Miranda J; Pérez-Jiménez F
    J Heart Lung Transplant; 1995; 14(3):461-7. PubMed ID: 7654731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia.
    Tesone PA; Gladstein J; Acuña AM
    Curr Med Res Opin; 1985; 9(9):650-7. PubMed ID: 3902379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of bezafibrate on disorders of lipid metabolism].
    Stryjek-Kamińska D; Ilińska-Debniak K; Bartosiewicz W; Szczepanik Z
    Pol Tyg Lek; 1983 Dec; 38(50):1567-71. PubMed ID: 6379618
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia.
    Hailer S; Pogarell O; Keller C; Wolfram G
    Arzneimittelforschung; 1996 Sep; 46(9):879-83. PubMed ID: 8876936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study.
    Ikewaki K; Noma K; Tohyama J; Kido T; Mochizuki S
    Int J Cardiol; 2005 Jun; 101(3):441-7. PubMed ID: 15907413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
    Kehely A; MacMahon M; Barbir M; Wray R; Hunt BJ; Prescott RJ; Thompson GR
    QJM; 1995 Jun; 88(6):421-7. PubMed ID: 7648234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
    Nye ER; Sutherland WH; Temple Wa
    N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia].
    Lechleitner M; Sailer S; Irsigler H; Klein W; Patsch JR
    Wien Med Wochenschr; 1995; 145(21):577-83. PubMed ID: 8560901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.
    Smud R; Sermukslis B
    Curr Med Res Opin; 1987; 10(9):612-24. PubMed ID: 3436157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
    Yeshurun D; Abukarshin R; Elias N; Lanir A; Naschitz JE
    Clin Ther; 1993; 15(2):355-63. PubMed ID: 8519043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.